Comparison of QR 678 & QR678 Neo as Monotherapy and as Combination Therapy with 5% Minoxidil Solution and Oral Finasteride in the Treatment of Male Androgenetic Alopecia Which is Better?

Hair is an essential aspect of image and is correlated with youth,
elegance, fitness, and achievement. Hair loss leads to lowered
self-esteem, lack of confidence and depression among affected
individuals.1
The US Food and Drug Administration (FDA) permit-
ted management options for male androgenetic alopecia (AGA) are
topical Minoxidil and oral Finasteride. These agents are beneficial in
controlling hair loss, but can only induce minimal new hair growth.2

A new formulation, introduced by Kapoor and Shome in 2018
named QR678 Neo® (US patent 2017, Indian Patent & Indian FDA
approval 2019), is a plant-derived polypeptide solution which com-
prises of concentration of biomimetic peptides in a titrated manner.3
QR678 Neo® already proved its effectiveness in hair regrowth ther-
apy for male and female pattern hair loss, and has also been to be
more efficacious than PRP.4,5

For full article open PDF